In a groundbreaking development, politicians are now taking notice of a revolutionary cancer breath test, offering a glimmer of hope in the fight against a deadly disease. But is this innovation too good to be true?
Shadow Health Secretary Stuart Andrew and Shadow Cancer Minister Caroline Johnson recently visited the scientists at Imperial College London who are developing a breath test for pancreatic cancer, a world-first achievement. The team, led by Professor George Hanna, is working towards a pan-cancer breath test, a device that could detect various gastrointestinal cancers.
This breathalyser-style device is currently being trialed on a national scale with over 6,000 patients whose diagnoses are unknown. If proven successful, it could save thousands of lives annually from the UK's deadliest common cancer.
The Imperial laboratory, funded in part by Pancreatic Cancer UK and supported by the Imperial College Healthcare NHS Trust, is at the forefront of this research. Professor Hanna's team has already made significant progress, analyzing 700 breath samples in a two-year clinical study, VAPOR, with promising results.
And here's where it gets controversial: The breath test could be available for general practitioners (GPs) within five years, but the question remains—is this timeline realistic?
Currently, there is no early detection test for pancreatic cancer, and no screening programs exist. GPs can only request scans or further investigations when patients present with symptoms, which are often vague and similar to less serious conditions. This diagnostic challenge leads to 80% of people receiving a late-stage diagnosis, with over half of patients tragically dying within three months.
The breath test works by detecting volatile organic compounds (VOCs) in the breath. These compounds, which travel through the bloodstream and are filtered by the lungs, differ in people with cancer, even in the early stages. By identifying unique VOC combinations, doctors could quickly triage patients likely to have pancreatic cancer for urgent investigation.
Professor Hanna's vision is clear: "The pan-cancer breath test will increase the chances of adoption by healthcare systems globally." Initial research suggests that unique VOC combinations can be identified for various gastrointestinal cancers, including pancreatic, oesophageal, gastric, liver, and colorectal cancers.
Alfie Bailey-Bearfield, from Pancreatic Cancer UK, expressed enthusiasm: "We're thrilled that politicians are engaging with this technology, which could save thousands of lives annually. While it may take years to reach GPs, the potential is undeniable." But is this optimism shared by all?
As the breath test progresses to a national clinical trial, the road to regulatory approval and NHS adoption becomes clearer. However, the timeline and potential challenges of implementing this technology in healthcare systems worldwide remain a topic of debate. Will this innovation truly revolutionize cancer detection, or are there hidden obstacles that may hinder its widespread adoption?
